J&J to Accelerate Development of Potential Coronavirus Vaccine

J&J’s Janssen Pharmaceutical will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority.

• The collaborative partnership with BARDA builds on Johnson & Johnson’s multipronged response to the new coronavirus disease outbreak.
• Janssen and BARDA will both contribute to R&D costs and mobilize resources to rapidly advance the initial stages of Janssen’s COVID-19 vaccine development program

To view the source of this information click here

To contact the reporter on this story:
Hari Govind in San Francisco at hgovind@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net ...